List of Excipients in Branded Drug TRIFLURIDINE

« Back to Dashboard

Generic Drugs Containing TRIFLURIDINE

Company	Ingredient	NDC	Excipient
Hi-Tech Pharmacal Co Inc	trifluridine	50383-955	ACETIC ACID
Hi-Tech Pharmacal Co Inc	trifluridine	50383-955	SODIUM ACETATE
Hi-Tech Pharmacal Co Inc	trifluridine	50383-955	SODIUM CHLORIDE
Hi-Tech Pharmacal Co Inc	trifluridine	50383-955	THIMEROSAL
Hi-Tech Pharmacal Co Inc	trifluridine	50383-955	WATER
Sandoz Inc	trifluridine	61314-044	ACETIC ACID
Sandoz Inc	trifluridine	61314-044	SODIUM ACETATE

What are the Most Frequently-Used Excipients in TRIFLURIDINE?

# Of NDCs	Excipient
2	ACETIC ACID
2	SODIUM ACETATE
2	SODIUM CHLORIDE
2	THIMEROSAL
1	WATER

Trifluridine Excipient Strategy and Commercial Opportunities

Last updated: August 16, 2026

Trifluridine has two distinct formulation markets: a 1% ophthalmic antiviral solution sold as Viroptic and an oral fixed-dose antineoplastic combination with tipiracil hydrochloride sold as Lonsurf. The strongest excipient opportunities are in differentiated oral dosage forms, preservative-optimized ophthalmic products, pediatric or dysphagia-friendly presentations, and manufacturing platforms that improve stability, dose uniformity, or patient handling.

Lonsurf’s established tablet formulation limits the commercial value of simple excipient substitution. A successful product generally needs a clear advantage, such as liquid dosing, orally disintegrating delivery, improved swallowability, lower exposure to hazardous powder, or a formulation that supports a regulatory pathway distinct from a conventional tablet generic.

What pharmaceutical products contain trifluridine?

Trifluridine is a thymidine nucleoside analog. Its commercial uses differ sharply by route, dose, and regulatory status.

Product	Active ingredients	Dosage form	Main indication	Regulatory position
Viroptic	Trifluridine 1%	Ophthalmic solution	Herpes simplex keratoconjunctivitis and epithelial keratitis	FDA-approved product
Lonsurf	Trifluridine and tipiracil hydrochloride	Film-coated tablet	Metastatic colorectal cancer and metastatic gastric or gastroesophageal junction cancer	FDA-approved combination product
Lonsurf plus bevacizumab	Trifluridine, tipiracil hydrochloride, and bevacizumab	Oral tablet plus intravenous biologic	Previously treated metastatic colorectal cancer	FDA-approved combination regimen

Lonsurf tablets contain trifluridine and tipiracil in a fixed molar relationship. The labeled strengths are 15 mg trifluridine/6.14 mg tipiracil hydrochloride and 20 mg trifluridine/8.19 mg tipiracil hydrochloride. The tablets are administered twice daily on Days 1 through 5 and Days 8 through 12 of a 28-day cycle, subject to dose modification.

The oral product is marketed by Taiho Pharmaceutical and distributed in the United States by Taiho Oncology. Viroptic has had a different commercial history, with availability and marketing arrangements changing over time.

What excipients are used in approved trifluridine products?

Lonsurf tablet excipients

The Lonsurf tablet uses a conventional immediate-release solid oral formulation. The inactive ingredients identified in the US prescribing information include:

• Lactose monohydrate
• Pregelatinized starch
• Colloidal silicon dioxide
• Magnesium stearate
• Hypromellose
• Titanium dioxide
• Talc
• Colorants, including ferric oxide pigments depending on tablet strength

The core excipient system supports direct compression or granulation, tablet mechanical strength, disintegration, and film-coating performance. It is not a modified-release platform. The principal commercial constraint is that a generic applicant must reproduce the relevant product quality attributes while managing the separate analytical and regulatory requirements associated with the fixed-dose combination.

Viroptic ophthalmic excipients

Viroptic is a sterile aqueous ophthalmic solution containing trifluridine at 1%. The labeled formulation includes sodium chloride, benzalkonium chloride, hydrochloric acid or sodium hydroxide for pH adjustment, and water for injection.

The ophthalmic formulation has a different excipient risk profile from Lonsurf. Preservative concentration, ocular tolerability, pH, osmolality, microbial control, container compatibility, and extractables and leachables are central development issues. Benzalkonium chloride can create tolerability concerns with frequent dosing or compromised ocular surfaces, creating a potential niche for preservative-reduced or preservative-free presentations if a commercially viable container system is developed.

Which excipient strategies offer the strongest commercial opportunities?

The highest-value opportunities are not simple replacement of lactose, starch, or magnesium stearate. They involve dosage-form differentiation and manufacturing risk reduction.

1. Oral liquid or reconstitutable suspension

An oral liquid could address patients with dysphagia, feeding tubes, or difficulty swallowing tablets. The technical barriers are substantial:

• Chemical stability of trifluridine and tipiracil in aqueous media
• Control of degradation products
• Dose uniformity after shaking
• Sedimentation and redispersibility
• Taste masking
• Microbial preservation
• Compatibility with enteral feeding tubes
• Occupational controls for a cytotoxic antineoplastic

A dry powder for reconstitution could reduce water-mediated degradation during storage. Sachets or unit-dose bottles could improve dose accuracy and reduce caregiver handling. The formulation would need to establish whether the product is therapeutically substitutable with Lonsurf or requires a separate clinical bridging strategy.

Taste masking is commercially relevant because trifluridine and tipiracil may produce unacceptable bitterness in a liquid product. Ion-exchange resins, polymeric coating, lipid-based barriers, and pH-controlled systems are candidate technologies. The selection must avoid delaying release or changing the exposure relationship between the two active ingredients.

2. Orally disintegrating or mini-tablet dosage forms

An orally disintegrating tablet could improve administration for patients with swallowing difficulty without introducing the stability burden of an aqueous liquid. Suitable excipient platforms may include:

• Crospovidone or croscarmellose sodium for rapid disintegration
• Mannitol or isomalt for mouthfeel
• Low-moisture binders
• Direct-compression excipients
• Taste-masking coatings
• Low-dust granulation systems

The main regulatory issue is whether the new presentation can rely on comparative dissolution and bioequivalence or whether food effect, absorption, or pharmacokinetic differences require additional clinical work. Because Lonsurf is a cytotoxic drug, minimizing friability and powder generation is also a manufacturing and occupational-health objective.

3. High-containment excipient and process design

Trifluridine products require containment controls during dispensing, blending, granulation, compression, coating, and packaging. Excipient selection can reduce process hazards by improving:

• Granule density
• Flowability
• Dust suppression
• Blend uniformity
• Tablet robustness
• Automated transfer
• Cleaning validation

A high-density, low-dust excipient system may have commercial value even if the final dosage form remains an immediate-release tablet. Contract manufacturers that can handle cytotoxic compounds while maintaining reproducible content uniformity are potential licensing or supply partners.

4. Preservative-optimized ophthalmic solutions

For trifluridine ophthalmic products, commercial differentiation may come from delivery and tolerability rather than from a new active ingredient.

Potential approaches include:

• Preservative-free single-dose containers
• Lower-preservative multidose systems
• Compatible antimicrobial packaging
• Low-surface-tension systems
• Reduced-volume droppers
• Improved nozzle geometry
• Unit-dose packaging for ophthalmology clinics

A preservative-free product would face higher packaging costs and more complex aseptic processing. It could still support premium pricing if it demonstrates improved ocular comfort, reduced preservative exposure, or better use in patients with recurrent ocular disease.

What formulation patents are likely to protect trifluridine products?

Trifluridine formulation protection can arise from several claim categories:

1. Composition claims covering trifluridine with tipiracil or related ratios.
2. Pharmaceutical composition claims covering tablet excipients and dosage ranges.
3. Method-of-use claims covering colorectal, gastric, or gastroesophageal cancer treatment.
4. Combination-treatment claims covering Lonsurf with bevacizumab.
5. Ophthalmic formulation claims covering concentration, pH, preservative system, or dosing.
6. Manufacturing claims covering granulation, coating, containment, or impurity control.
7. Packaging claims covering cytotoxic handling or sterile multidose delivery.

The commercial importance of excipient patents depends on claim breadth. A patent covering “trifluridine plus a disintegrant” may be weak if the excipient is conventional and predictable. A patent covering a defined stability profile, impurity threshold, dissolution window, or preservative-free container system may create stronger design-around barriers.

For an oral generic, the most relevant legal work typically involves the FDA Orange Book, listed patents, Paragraph IV certifications, and the relationship between product patents and method-of-use patents. A generic applicant can challenge listed patents while carving out protected uses through a section viii statement where permitted. A formulation that avoids the branded tablet’s specific excipient or process claims may reduce litigation exposure, but it does not eliminate composition or method-of-use risk.

When does trifluridine exclusivity expire?

Lonsurf received FDA approval in 2015 for metastatic colorectal cancer. Its later FDA approvals expanded the labeled patient population, including metastatic gastric or gastroesophageal junction cancer and the combination with bevacizumab for previously treated metastatic colorectal cancer.

Exclusivity category	Relevance to trifluridine	Commercial effect
New chemical entity exclusivity	Applied to the initial approved product if awarded	Blocks abbreviated approval for five years from initial approval, subject to statutory exceptions
Orphan-drug exclusivity	May attach to a specific orphan indication, not automatically to every use	Can restrict approval of the same drug for the protected disease indication for seven years
Pediatric exclusivity	Depends on completion of an FDA written-request program	Can add six months to qualifying exclusivity and patent periods
Patent exclusivity	Depends on listed patents, patent term adjustment, and any term extension	Can delay approval or launch of competing products
Regulatory exclusivity for later indications	Usually does not recreate full NCE exclusivity	Protects only the statutory scope of the relevant approval

The original five-year NCE period for a 2015 approval is no longer the principal barrier. Patent and indication-specific protections remain more important for current generic-entry analysis. FDA approval status and Orange Book listings must be assessed by product, strength, patent number, and protected use.

What Paragraph IV challenges and generic entry risks exist?

A conventional Lonsurf generic would likely face several technical and legal issues:

• Demonstrating bioequivalence for a two-active-ingredient product
• Matching dissolution for both trifluridine and tipiracil
• Reproducing the labeled strength ratio
• Managing food-effect requirements
• Addressing tablet size and coating differences
• Certifying against Orange Book patents
• Carving out protected methods of use where legally available
• Controlling occupational exposure during manufacturing

A Paragraph IV filing could trigger patent litigation and a statutory stay of FDA approval for up to 30 months, subject to the timing and outcome of litigation. A first filer may pursue 180-day generic exclusivity if statutory conditions are satisfied. The practical launch date would depend on patent validity, enforceability, infringement findings, settlement terms, and any regulatory exclusivity remaining for the relevant indication.

The most exposed scenario is a conventional tablet generic with no meaningful formulation differentiation. The lower-risk commercial strategy is a product with a distinct excipient platform, a separate dosage-form rationale, or a geographic focus outside the United States where patent and regulatory barriers differ.

How does trifluridine compare with competing oncology and antiviral products?

Oral oncology competition

Lonsurf competes with other late-line colorectal and gastric cancer therapies, including regorafenib and targeted treatments selected according to biomarker status. Its commercial position depends on tolerability, survival benefit, treatment sequencing, reimbursement, and the increasing use of combination regimens.

The active ingredient is rarely dispensed as trifluridine alone in oncology. Tipiracil is essential because it inhibits thymidine phosphorylase and increases trifluridine exposure. This makes a single-agent trifluridine generic less commercially relevant for oncology unless it is part of a clinically supported combination.

Ophthalmic antiviral competition

Viroptic competes with ophthalmic and systemic antiviral treatment strategies, including ganciclovir ophthalmic gel and oral acyclovir or valacyclovir in selected clinical settings. The main excipient opportunity is a better-tolerated topical product, not a change in antiviral mechanism.

Attribute	Oral trifluridine/tipiracil	Ophthalmic trifluridine
Primary market	Oncology	Herpes simplex eye disease
Formulation priority	Dose uniformity and containment	Sterility, preservative tolerance, ocular comfort
Key commercial barrier	Patent, bioequivalence, oncology reimbursement	Clinical substitution and ophthalmic availability
High-value innovation	Liquid, ODT, low-dust tablet	Preservative-free or improved multidose delivery
Main excipient risk	Stability, dissolution, cytotoxic handling	Preservative toxicity, container compatibility

What manufacturing and intellectual-property barriers affect commercial entry?

Manufacturing capability is a meaningful barrier for oral trifluridine products. The product contains a potent antineoplastic active ingredient and requires segregation, validated cleaning, exposure monitoring, and controlled waste handling. A formulation that creates airborne powder during milling or compression may be commercially unattractive even if it performs well analytically.

For ophthalmic products, the critical barriers are aseptic manufacture, sterile filtration where applicable, preservative validation, container-closure integrity, and ophthalmic particulate control. Preservative-free systems require reliable single-use or multidose valve packaging and higher packaging-process control.

Excipient suppliers can capture value through proprietary grades, not only through novel chemical entities. A high-density direct-compression excipient, low-moisture platform, taste-masking polymer, cytotoxic containment process, or preservative-free ophthalmic container can become part of a defensible supply or licensing strategy.

What licensing opportunities exist for trifluridine excipients?

The most credible licensing targets include:

Oncology formulation partnerships

A specialty pharmaceutical company could license an oral liquid, ODT, mini-tablet, or low-dust tablet platform to a generic manufacturer or oncology-focused commercial partner. The asset would be more attractive if it has comparative dissolution, stability, pharmacokinetic, and handling data.

Ophthalmic delivery partnerships

Packaging companies, ophthalmic manufacturers, and sterile-fill contractors could collaborate on preservative-free or low-preservative trifluridine products. The commercial model could combine a proprietary container with a ready-to-file drug product.

Regional rights

Patent and regulatory exposure differ across the United States, Europe, Japan, and emerging markets. Regional licensing may be practical where local manufacturers have established sterile or cytotoxic capabilities and where the reference product is unavailable or expensive.

Excipient supply agreements

A supplier can pursue a long-term agreement tied to a generic launch, with volume commitments for a specialized excipient grade. This approach offers lower clinical risk than licensing a fully reformulated drug product but depends on the excipient becoming part of the approved commercial process.

How strong is the trifluridine excipient opportunity?

The opportunity is moderate for conventional tablets and stronger for differentiated delivery systems.

Opportunity	Technical complexity	Regulatory burden	Commercial potential
Conventional tablet excipient substitution	Low to moderate	Moderate	Low
Low-dust cytotoxic tablet platform	Moderate	Moderate	Moderate
Orally disintegrating tablet	Moderate to high	Moderate to high	Moderate
Oral liquid or suspension	High	High	High if clinically substitutable
Preservative-free ophthalmic solution	High	High	Moderate to high
Novel ophthalmic packaging	Moderate to high	Moderate to high	Moderate
Modified-release oncology product	High	High	Uncertain

The best near-term strategy is a formulation that solves a specific use problem and can be supported by a clear regulatory pathway. Excipient novelty alone is unlikely to justify a premium. Improved administration, reduced handling risk, better stability, or lower ocular irritation has stronger commercial relevance.

Key Takeaways

• Trifluridine has two distinct markets: Viroptic ophthalmic solution and Lonsurf oral oncology tablets.
• Lonsurf uses conventional tablet excipients, so simple substitution offers limited differentiation.
• Oral liquids, orally disintegrating tablets, mini-tablets, and low-dust cytotoxic formulations present the strongest oral opportunities.
• Preservative-free or preservative-optimized ophthalmic delivery is the leading topical opportunity.
• Tipiracil is essential to the oncology product’s clinical use, limiting the value of trifluridine-only oral products.
• Generic entry depends on bioequivalence, Orange Book patents, Paragraph IV strategy, indication carve-outs, and litigation outcomes.
• Specialized excipient grades, containment processes, taste-masking systems, and ophthalmic packaging can support licensing opportunities.
• The most defensible commercial assets combine excipient technology with stability, handling, and regulatory data.

FAQs

Can trifluridine be formulated as an oral liquid?

Yes. An oral liquid or powder for reconstitution could address dysphagia and feeding-tube use, but it would require control of chemical stability, taste, dose uniformity, preservation, and cytotoxic handling.

Is trifluridine a suitable candidate for an orally disintegrating tablet?

Yes. An orally disintegrating tablet could improve administration without the stability burden of an aqueous product. Taste masking, friability, dissolution, and bioequivalence would determine feasibility.

What is the main preservative concern for trifluridine eye drops?

The principal concern is benzalkonium chloride exposure, particularly with repeated dosing or compromised ocular surfaces. Preservative-free packaging could provide a differentiation route.

Does changing the excipients avoid Lonsurf patent risk?

Not necessarily. A reformulated product may still implicate composition, method-of-use, dosage-form, manufacturing, or listed Orange Book patents. Excipient changes must be evaluated against each patent claim.

Which excipient suppliers could benefit from trifluridine products?

Suppliers of low-dust direct-compression excipients, taste-masking polymers, moisture-controlled systems, specialized film coatings, and preservative-free ophthalmic containers are the most relevant potential beneficiaries.

References

1. FDA. (2015). Lonsurf prescribing information. U.S. Food and Drug Administration.

2. FDA. (2023). Lonsurf prescribing information. Taiho Oncology, Inc.

3. FDA. (n.d.). Drugs@FDA: Lonsurf. U.S. Food and Drug Administration.

4. FDA. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Food and Drug Administration.

5. FDA. (n.d.). Viroptic prescribing information. U.S. Food and Drug Administration.

6. National Library of Medicine. (n.d.). Trifluridine drug label information. DailyMed.